Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Tocris™ Ruxolitinib

Potent and selective JAK1/JAK2 inhibitor; orally bioavailable

Manufacturer:  Tocris™ 7064/50

Catalog No. 70-645-0


Add to cart
This item is not returnable. View return policy

Description

Description

Ruxolitinib is a potent and selective JAK1/2 inhibitor (IC50 values are 3.3 and 2.8 nM, respectively). Exhibits selectivity for JAK1/2 over Tyk2 and JAK3 (∽6-fold and >130-fold, respectively). Exhibits no significant inhibition against a commercial panel of 26 additional kinases. Inhibits JAK2V617F-mediated signaling and proliferation in Ba/F3 cells and HEL cells. Increases survival rates in a JAK2V617F-driven mouse model. Identified as targeting human host proteins that interact with SARS-CoV-2.Orally bioavailable.

Phosphate salt (Cat. No. 7048) also available.

Specifications

Specifications

(3 R)-3-Cyclopentyl-3-[4-(7 H-pyrrolo[2,3-d]pyrimidin-4-yl)-1 H-pyrazol-1-yl]propanenitrile
C17H18N6
JAK Kinase Inhibitors
50 mg
2323
98%
941678-49-5
Safety and Handling

Safety and Handling

Recommended Storage : Store at -20°C

SDS
Documents
Product Certifications
Promotions

Promotions

Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit